Renovaro Inc. (NASDAQ:RENB) stated that the Delaware Court of Chancery has granted an expedited trial to its action against Predictive Oncology Inc. (NASDAQ:POAI), which was filed on May 9, 2025.
A laboratory technician researching a sample of cells in a biotechnology laboratory.
A binding merger agreement signed on January 1, 2025, which called for Predictive Oncology to merge into Renovaro Inc. in exchange for a new class of preferred stock, is being enforced in this action (No. 2025-0509). According to Renovaro’s complaint, POAI violated the terms of exclusivity and good faith by launching a $545,000 public securities offering on February 19, 2025, and then making an attempt to unilaterally end the agreement on April 3, 2025. Renovaro Inc. is seeking damages, injunctive relief, and specific performance.
The case focuses on a Letter Agreement that caused POAI’s share price to rise by more than 50% and was made public in a January 6, 2025, Form 8-K. Renovaro Inc. asserts that POAI’s activities, which breached the agreed-upon confidentiality and did not participate in substantive negotiations toward a final agreement, violated the conditions of the merger.
Renovaro Inc. is a TechBio business that specializes in cancer treatments, drug development, and diagnostics. Among its subsidiaries are BioSymetrics (AI for precision neurology), RenovaroBio (cell-gene immunotherapy), and RenovaroCube (AI-driven diagnostics and drug development). Concerns about shareholder value and legal attempts to uphold M&A agreements are brought to light in this case.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
